These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

588 related items for PubMed ID: 29254377

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U, Signore PE, Walkinshaw G, Seeley TW, Brenner MC, Wang Q, Guo G, Arend MP, Flippin LA, Chow FA, Gervasi DC, Kjaergaard CH, Langsetmo I, Guenzler V, Liu DY, Klaus SJ, Lin A, Neff TB.
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [Abstract] [Full Text] [Related]

  • 5. Roxadustat: First Global Approval.
    Dhillon S.
    Drugs; 2019 Apr; 79(5):563-572. PubMed ID: 30805897
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
    Akizawa T, Yamaguchi Y, Majikawa Y, Reusch M.
    Ther Apher Dial; 2021 Oct; 25(5):575-585. PubMed ID: 33200512
    [Abstract] [Full Text] [Related]

  • 12. The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia.
    Su K, Li Z, Yu Y, Zhang X.
    Drug Discov Today; 2020 Jul; 25(7):1262-1269. PubMed ID: 32380083
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease.
    Kurata Y, Tanaka T, Nangaku M.
    Expert Opin Pharmacother; 2022 Jan; 23(1):19-28. PubMed ID: 34686069
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.
    Locatelli F, Minutolo R, De Nicola L, Del Vecchio L.
    Drugs; 2022 Nov; 82(16):1565-1589. PubMed ID: 36350500
    [Abstract] [Full Text] [Related]

  • 17. Development of a health economic model to evaluate the cost-effectiveness of roxadustat in treating anemia associated with non-dialysis-dependent chronic kidney disease.
    Mata Lorenzo M, Ali M, Mealing S, Moss J.
    J Med Econ; 2023 Nov; 26(1):1250-1260. PubMed ID: 37752891
    [Abstract] [Full Text] [Related]

  • 18. A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat.
    Becker K, Saad M.
    Adv Ther; 2017 Apr; 34(4):848-853. PubMed ID: 28290095
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis.
    Tian L, Wang M, Liu M, Pang Y, Zhao J, Zheng B, Wang Y, Zhao W.
    Ren Fail; 2024 Dec; 46(1):2313864. PubMed ID: 38345037
    [Abstract] [Full Text] [Related]

  • 20. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
    Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M.
    J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.